On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was 1.43% up from the session before settling in for the closing price of $2.10. A 52-week range for TSHA has been $1.05 – $4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 94.30% over the last five years. When this article was written, the company’s average yearly earnings per share was at 3.49%. With a float of $165.06 million, this company’s outstanding shares have now reached $204.94 million.
The firm has a total of 73 workers. Let’s measure their productivity. In terms of profitability, gross margin is 100.0%, operating margin of -1097.55%, and the pretax margin is -1071.62%.
Taysha Gene Therapies Inc (TSHA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 19.51%, while institutional ownership is 77.18%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 3.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.17% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 52.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.42 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Analysing the last 5-days average volume posted by the [Taysha Gene Therapies Inc, TSHA], we can find that recorded value of 4.63 million was better than the volume posted last year of 2.36 million. As of the previous 9 days, the stock’s Stochastic %D was 31.57%. Additionally, its Average True Range was 0.24.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 64.48%, which indicates a significant increase from 52.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 162.00% in the past 14 days, which was higher than the 106.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.67, while its 200-day Moving Average is $1.92. Now, the first resistance to watch is $2.21. This is followed by the second major resistance level at $2.30. The third major resistance level sits at $2.37. If the price goes on to break the first support level at $2.05, it is likely to go to the next support level at $1.98. Now, if the price goes above the second support level, the third support stands at $1.89.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 205,055K outstanding shares of the company, which has a market capitalization of 436.78 million. As of now, sales total 8,330 K while income totals -89,300 K. Its latest quarter income was 2,020 K while its last quarter net income were -18,780 K.
